miR-149-3p targeting TMPRSS4 regulates the sensitivity to cisplatin to inhibit the progression of lung cancer
2024

miR-149-3p and Lung Cancer: Enhancing Sensitivity to Cisplatin

Sample size: 45 publication 10 minutes Evidence: high

Author Information

Author(s): Qin Beibei, Tang Dongfang, Zhang Mingzhi

Primary Institution: The First Affiliated Hospital of Zhengzhou University

Hypothesis

miR-149-3p enhances the sensitivity of lung cancer cells to cisplatin by targeting TMPRSS4.

Conclusion

Overexpression of miR-149-3p inhibits lung cancer progression and increases the responsiveness of cancer cells to cisplatin.

Supporting Evidence

  • miR-149-3p levels were significantly lower in lung cancer tissues compared to adjacent normal tissues.
  • Overexpression of miR-149-3p inhibited cell proliferation and promoted apoptosis in lung cancer cells.
  • TMPRSS4 was identified as a target of miR-149-3p, and its overexpression reduced the sensitivity of lung cancer cells to cisplatin.
  • Animal studies showed that miR-149-3p overexpression reduced tumor size and enhanced chemosensitivity.

Takeaway

This study shows that a tiny molecule called miR-149-3p can help lung cancer cells respond better to a medicine called cisplatin, which is used to treat cancer.

Methodology

The study involved analyzing miR-149-3p levels in lung cancer tissues and cells, creating DDP-resistant cell lines, and using various assays to assess cell behavior and tumor growth in mice.

Limitations

The study primarily focuses on the role of miR-149-3p in lung cancer and does not explore other potential factors influencing DDP resistance.

Participant Demographics

All participants were treatment-naive lung cancer patients aged 18 and older.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.17305/bb.2024.11163

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication